JTCS Speed Up Your Browser
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Floyd D. Loop
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shainoff, J. R.
Right arrow Articles by Loop, F. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shainoff, J. R.
Right arrow Articles by Loop, F. D.

J Thorac Cardiovasc Surg 1994;108:437-445
© 1994 Mosby, Inc.

CARDIOPULMONARY BYPASS,
MYOCARDIAL MANAGEMENT, AND SUPPORT TECHNIQUES

Low factor XIIIA levels are associated with increased blood loss after coronary artery bypass grafting

John R. Shainoff, PhD, F. George Estafanous, MD, Jean-Pierre Yared, MD, Patricia M. DiBello, MS, Kandice Kottke-Marchant, MD, PhD, Floyd D. Loop, MD


Cleveland, Ohio

Supported in part by grant HL-16361 from the National Heart, Lung, and Blood Institute, National Institutes of Health.

Received for publication Aug. 10, 1993. Accepted for publication Feb. 14, 1994. Address for reprints: John R. Shainoff, PhD, Research Institute NC3, Cleveland Clinic, 9500 Euclid Ave., Cleveland, OH 44195.

Abstract

Current hematologic approaches to minimize postoperative bleeding have focused principally on antifibrinolytic agents. To explore whether a need might exist to promote clot stabilization independent of steps that might be taken to prevent lysis, we followed levels of the functional A-chain of factor XIII (fibrin stabilizing factor) immunologically in 19 patients undergoing coronary artery bypass grafting. The levels of factor XIIIA together with alterations in fibrinogen were followed at five stages of operation: (1) initial catheter placement (control), (2) heparinization, (3) initiation of cardiopulmonary bypass, (4) discontinuation of cardiopulmonary bypass, and (5) heparin neutralization with protamine sulfate. Significant (p < 0.05) inverse correlations were observed between postoperative chest-tube drainage volumes and levels of XIIIA at stages 1 through 3, and borderline associations (p < 0.1) were observed for stages 4 and 5. Pronounced losses of factor XIIIA accompanied initiation of cardiopulmonary bypass, when levels fell to 43%±12% (standard deviation) of the control value, significantly below the 59%±9% of the control value expected from hemodilution. By comparison, fibrinogen concentrations fell only to the extent attributable to hemodilution, unaccompanied by substantial degradation as indicated by electrophoretic, functional, and immunologic assays. There was a reversible heparin-induced precipitation of fibrin complexes and fibrinogen dimers from the blood on initiation of hypothermia, but these components returned to the circulation on restoration of normothermia. This precipitation was unrelated to losses of factor XIIIA. The findings warrant inference that XIIIA supplementation in deficient states should be considered as an adjunct to other therapies for postoperative bleeding. (J THORAC CARDIOVASC SURG1994;108:437-45)

Because of risks associated with transfused blood, strong attention is being directed to minimizing blood loss during and after cardiothoracic surgical procedures. Go 1 It is well known that cardiopulmonary bypass (CPB) can affect coagulation factors and platelets to predispose bleeding. Go 2 Recent studies have demonstrated improved hemostasis and reduced blood requirements in patients who received antifibrinolytic agents Go Go 3-6 and especially marked improvement with high doses of aprotinin before CPB. Go Go 7-11 Yet, postoperative bleeding persists along with formation of "soft clots" in some patients despite the minimization of clot lysis. We sought to determine whether a need might exist to promote the stabilization of clots independent of the steps that can be taken to prevent their lysis. To that end, we followed changes in immunologic levels of the functional A-chain of factor XIII (fibrin stabilizing factor) and made an assessment of the alterations in the condition and concentration of fibrinogen that accompany coronary artery bypass grafting (CABG).

METHODS

Human subjects
The study group included 19 randomly selected adult patients (15 men, 4 women) scheduled to undergo elective primary CABG. Patients on a long-term regimen of ß-adrenergic or calcium entry blockers continued to receive these medications until the morning of the operation. Selection and dosage of the drugs used for anesthetic premedication, induction, and maintenance were determined by the anesthesiologist according to patient condition and were not affected by participation in the study. Anesthetic management was done according to the usual practice in our institution and included electrocardiographic and hemodynamic monitoring. Induction and maintenance of anesthesia were obtained with a combination of narcotics, benzodiazepines, and neuromuscular blockers with supplemental administration of low concentrations of a potent inhalational agent (enflurane or isoflurane) when appropriate. At the election of the surgeon, CPB was done with the use of hypothermia (28° C) in 14 patients and normothermia (35° C) in 5 patients with no consideration for interests of this study. There were no deviations from the usual standards of care during the entire perioperative period.

Laboratory analyses done for this study required only fractional milliliter quantities of blood, which were derived from portions that would ordinarily be discarded from samples taken as part of routine monitoring of the hematocrit value, blood gases, and coagulation status of the patients during the operation. The analyses were made on blood samples taken (1) at the initial catheter placement before heparinization, (2) after the heparinization (initially 300 U/kg, followed by titration to produce an approximately 480-second activated whole blood clotting time), (3) after initiation of CPB, (4) at completion of operation and discontinuation of CPB, and (5) after heparin neutralization with protamine sulfate. Because no special or additional blood samples were taken, and because the study involved no deviations from standard protocols for CABG regularly used by the departments of cardiothoracic surgery and anesthesia at the institution, it qualified for exemption No. 5 under National Institutes of Health guide lines.

Blood loss
The extent of postoperative bleeding was estimated from the recorded volumes of chest-tube drainage collected over a 24-hour period in the intensive care unit after operation. Measurements of intraoperative blood loss, from accounts of aspirated blood and sponge weights, Go 12 would have imposed significant changes inprotocol. Go 13 The blood conservation techniques currently used at our institution allow the return of all the blood collected intraoperatively in the extracorporeal circuit and suction bottles, and these conservation techniques were applied without deviation, as described. Go 14

Calculations of the theoretic dilutions of fibrinogen that would be expected from hemodilution during CPB were based in part on (1) the calculated change in plasma protein concentrations (PD/PU, diluted/undiluted) as a function of change in hematocrit (HD and HU, percent blood volume) that would accompany a simple dilution of the blood without any reequilibration (PD/PU = [HD(100 - HU)]/[HU(100 - HD)]) and (2) an adjustment based on consideration that approximately 20% of the total fibrinogen is extravascular and would reequilibrate with the diluted plasma. Go Go 15,16 Thus the expected percentage of initial concentration (%Co) would be given by %Co = 20% + 80%(PD/PU). The percentage extravascular exchangeable factor XIIIA has not been determined, but may be the same as that of fibrinogen because of indications that it circulates in association with fibrinogen. Go 17

Laboratory materials
Purchased media for electrophoretic characterizations of fibrin(ogen) were as described in previous studies, Go Go 18,19 as were the substances used as preservatives of the blood samples (aprotinin, heparin, glycylprolylarginine [GPR]). Purified recombinant factor XIIIA (rXIIIA) from yeast was a gift from Dr. Paul Bishop (Zymogenetics, Seattle, Wash.). Proteins prepared in-house were fibrinogen and antibodies to it and its component polypeptide chains, as described. Go 18

Assays
Blood samples were taken into Vacutainer tubes (Becton Dickinson Inc., Oxnard, Calif.) that contained ethylenediaminetetraacetic acid (EDTA), except for samples for determination of fibrinogen by the Clauss Go 20 method, for which citrate was used as the anticoagulant. The samples were centrifuged within 2 hours after the operation, and a portion (0.2 ml) of each EDTA/plasma sample was diluted with an equal volume of preservative cocktail that contained 10 U/ml heparin, 0.24 TIU/ml aprotinin, and 5 mmol/L GPR for the electrophoretic and immunologic analyses. For sodium dodecylsulfate (SDS) electrophoresis, 50 µl portions of the diluted samples were diluted further in half (1/4 overall) with 4% SDS that contained 2% mercaptoethanol, and another portion was diluted with SDS without mercaptoethanol.

Factor XIIIA levels were determined by enzyme-linked immunosorbent assay with commercial goat antihuman factor XIII (A-chain and B-chain) antibodies (American Diagnostica Inc., Greenwich, Conn.) applied (18 hours, 4° C) at a level of 5 µg/ml (0.1 ml, 0.05 mol/L Tris buffer in 0.15 mol/L NaCl at pH 9.2) to coat as the "capture antibody" on 96-well flexible assay dishes (Falcon MicroTest III, Becton Dickinson Inc.), which were subsequently blocked (3 hours, 37° C) with 3% bovine serum albumin in phosphate-buffered saline containing 0.05% Tween 20 (PBS-Tween). Samples at four dilutions (1, 0.75, 0.5, and 0.25 x 1:1000) and standard plasma (CTS standard plasma, Behring Diagnostics, Inc., Somerville, N.J.) and rXIIIA (2 ng/ml to 1 µg/ml) in PBS-Tween with 4 mmol/L EDTA were applied (0.1 ml) and then washed after 18 hours at 4° C. The captured antigen was then measured by incubation with polyclonal rabbit antihuman factor XIIIA antibody (Calbiochem Corp., San Diego, Calif.) for 2 hours at 20° C, followed by a rinse and a 2-hour incubation with 0.1 ml of a 1:1000 dilution of horseradish peroxidase–swine antirabbit immunoglobulin G antibodies (DAKO Corp., Cartinteria, Calif.) in PBS-Tween. After washing, the retained horseradish peroxidase was measured from colored peroxidase reaction product formed in 10 minutes from 3.3 µmol/L o-phenylenediamine (Sigma Chemical Co., St. Louis, Mo.) in 0.1 mol/L NA2HPO4/0.05 mol/L citric acid/0.02% H2O2 in the dark at 20° C. Product formation was stopped with 50 µl of 10 N H2SO4 and was measured on a Bio-Tek EL 310 EIA Autoreader (Bio-Tek Instruments Inc., Burlington, Vt.) using dual wavelength settings of 490 and 600 nm. Readings were converted to XIIIA concentrations by calculation from fourth-order polynomial curve fitting (r = 0.99) of concurrently analyzed dilutions of plasma standards, the curve fitting being done by SlideWrite version 5.0 software (Advanced Graphics Software, Carlsbad, Calif.). Because this enzyme-linked immunosorbent assay method has not been described previously, a typical calibration curve relating factor XIIIA concentrations to absorbance is shown (Fig. 1). The factor XIIIA levels in the normal plasma standard (Berichrom normal plasma, Behring Diagnostics) corresponded to 9.3 ± 0.9 µg/ml, determined with the use of rXIIIA as a primary standard. Go 21 The immunologic levels of XIIIA in dilutions of the plasma standards (Behring Diagnostics) correlated with activity assays performed on them (r = 0.97, n = 12).



View larger version (11K):
[in this window]
[in a new window]
  		Fig. 1. Calibration curves used for measuring factor XIIIA by enzyme-linked immunosorbent assay by comparison of color development from commercial plasma standard and known amounts of recombinant XIIIA, which served as primary standard.

 
Functional fibrinogen levels were determined with commercial kits for the Clauss method (Dade Data-Fi, Baxter Healthcare Corp., Miami, Fla.) on the basis of thrombin time. Go 20 Immunologic determinations of total fibrinogen-related antigen were done by Laurell rocket electrophoresis with (1) the general protocol for the electrophoresis as detailed by Weeke Go 22 and (2) antigen-precipitating gelcontaining affinity purified Go 18 rabbit antihuman fibrinogen antibodies at a concentration of 25 µg/ml for assay of 1.0 µl samples of plasma diluted 1:1 in running buffer (6 mmol/L sodium barbital, 1 mmol/L barbital, 75 mmol/L glycine, 37 mmol/L Tris buffer, and 1 mmol/L EDTA, pH 8.6). Fibrin monomers were detected electrophoretically by GPR-phoresis as described. Go 19 Separate electrophoretic determinations of the polypeptide subunits of fibrinogen and its derivatives in the plasma samples were done by a direct immunoprobing procedure with glyoxyl agarose/polyacrylamide composite gels as described. Go Go 18,23

RESULTS

As illustrated (Fig. 2), subjects with high concentrations of plasma factor XIIIA tended to have less than average postoperative bleeding, determined from chest-tube drainage. This inverse relationship was statistically significant (p < 0.05) for the levels of XIIIA measured at stages 1 through 3 (preoperatively through the initiation of CPB), but only bordered on significance (p < 0.1) for stages 4 and 5 (after termination of CPB and administration of protamine). The significant correlations (r = 0.52 and 0.50 at stages 1 and 3) became blunted by a substantial 50% rise in the levels of XIIIA in two subjects who had low values at stage 3.



View larger version (69K):
[in this window]
[in a new window]
  		Fig. 2. Relationships between volume of chest-tube drainage and levels offactor XIIIA in plasma samples taken before catheterization (dots) and after initiation of CPB (boxes) in 19 patients (stages1 and 3). Lines depict regression assessed by least-squares yielding correlation coefficients equal to or slightly greater than 0.50 for both stages. Shaded areas span 70% confidence limits.

 
The preoperative levels of factor XIIIA (Co) ranged widely, with nine tenths of the subjects having concentrations between 200% and 50% of that of the pooled normal plasma standard (Fig. 2). It was not determined whether this variability was greater than normal because there was little literature on immunoassays of XIIIA; however, the average of the levels for all subjects was essentially the same (112% ± 13.8%, standard error of the mean) as that in the commercial standard for normal plasma. As might be anticipated, there was no effect of heparin administration on the immunologically determined levels of XIIIA, with no significant difference between the measurements at stages 1 and 2 as determined by paired t test. In studies not reported here the heparin adversely affected measurements of factor XIIIA activity by interfering with thrombin activation of the XIIIA. Also, as could be anticipated as a result of hemodilution from the fluid used for priming the pump and oxygenator, the levels of XIIIA fell precipitously during initiation of CPB (Fig. 3). However, the levels of XIIIA fell considerably lower than could be attributed to hemodilution, as judged by comparison with fibrinogen levels, which fell only to the extent attributable to hemodilution (Fig. 3). After initiation of CPB, the XIIIA levels fell to 43% ± 12% (standard deviation) of their initial (Co) values, whereas fibrinogen fell only to 58% ± 11% (standard deviation) of Co. Levels of XIIIA less than 30% of normal were found in 6 of the 19 patients at stage 3.



View larger version (68K):
[in this window]
[in a new window]
  		Fig. 3. Changes in hematocrit (Hct) and plasma fibrinogen(Fgnobs) and factor XIIIA concentrations relative to initial values just before operation in 19 subjects undergoing CABG. Expected dilutions of fibrinogen (Fgncalc) calculated from changes in hematocrit are also shown for comparison with observed values. Apart from initial (PreOp) samplings, samples were taken after administration of heparin (Hep), initiation of CPB (CPB), removal of bypass (Post), and administration of protamine sulfate (Prot). Brackets represent standard deviations.

 
Fibrinogen concentrations determined by the Clauss method on the basis of coagulability Go 20 were essentially coincident with concentrations determined by immunoassay (Fig. 4). The agreement between the functional and immunologic determinations provided an indication that degradation contributed negligibly to the decreased levels of fibrinogen seen on initiation of CPB. Direct assessments of the condition of fibrinogen were obtained from electrophoretic analyses that profiled (1) its concentrations in relation to its macromolecular derivatives (fibrin monomer complexes and fibrinogen dimers) as revealed by GPR-phoresis (Fig. 5) and (2) relative amounts of nondegraded and degraded polypeptide chains of the fibrinogen as revealed by SDS electrophoresis of thiol-reduced proteins (Fig. 6). SDS electrophoresis analyses of nonreduced proteins were also run for confirmatory purposes, but the results are not illustrated. These characterizations generally showed little or no change in the low-molecular-weight components relative to the undegraded molecules or their component chains in plasma from most subjects throughout the course of operation, as illustrated (Fig. 6). However, the concentrations of low-molecular-weight degradation products, which ranged between 2% and 5% of the total chains, were regularly elevated on the order of tenfold higher than normal in the preoperative samples from these subjects, presumably in association with the vascular disease. Two subjects showed a doubling of the low-molecular-weight components relative to nondegraded fibrinogen at stage 3, but because degraded chains comprised only a small percentage of the total fibrinogen their concentrations still remained small compared with levels of undegraded components.



View larger version (15K):
[in this window]
[in a new window]
  		Fig. 4. Comparison of functionally determined (Clauss) fibrinogen concentrations with immunologically determined levels in initial (stage 1) plasma samples (dots) and after initiation (stage 3) of CPB (boxes) in 9 patients studied by both methods. Solid line represents identity and dashed line is from least-squares regression.

 


View larger version (54K):
[in this window]
[in a new window]
  		Fig. 5. GPR-phoresis for determination of macromolecular derivatives of fibrin(ogen) in plasma. Peptide GPR was used to stage separation of fibrin monomer (position f1 on vertical scale) from fibrinogen dimers (Ø2) and normal monomeric fibrinogen (Ø1) on basis of their aggregation characteristics and molecular size. Fibrinogen derivatives were preferentially fixed by thermal denaturation at 47° C and stained with Coomassie blue. Middle lane, marked f1, shows a fibrinogen sample that was briefly exposed to thrombin to elicit fibrin monomer production for reference. Panel at left shows plasma samples from hypothermic subject (patient [Pt.] 15H) at stages 1 through 5 and additional sample 2 hours later. Highly elevated level of dimers in that subject disappeared from plasma after heparinization (stage 2) and initiation of hypothermia and then returned to plasma on restoration of normothermia (stage 5). Fibrin monomer level was not highly elevated in this subject, but it disappeared also in subjects in which it was initially elevated. Panel at right shows little change in either f1 or Ø2 relative to normal fibrinogen levels that accompanied operation under normothermic conditions in patient 17N. Pre, Preoperative; other abbreviations of sampling points as in Fig. 3.

 


View larger version (44K):
[in this window]
[in a new window]
  		Fig. 6. Electrophoretogram showing fibrinogen {gamma}-chains and {alpha}-chains and {alpha}/{gamma}-chain dimers in thiol-reduced plasma specimens from two patients (Pt. 1 and Pt. 2) at indicated stages of CABG under hypothermia. Electrophoretogram was initially immunoprobed with peroxidase-labeled anti-{gamma}-chain antibodies that were stained blue with 4-chloronaphthol and was then immunoprobed with anti-{alpha}-chain antibodies that were stained amber with diaminobenzidine, as described.Go 18 Commensurate staining of dimeric chains with anti-{gamma}-chain antibodies (not shown separately) and anti-{alpha}-chain antibodies indicated that most of dimeric chains were {alpha}/{gamma}-hybrids. As illustrated, electrophoretograms for both patients showed preferential loss of dimers after initiation of CPB and substantial return after removal of bypass (post) and added return after administration of protamine sulfate (protam). Pre-op, Preoperative.

 
As illustrated (Figs. 5 and 6), levels of fibrin monomers and fibrinogen dimers also were highly elevated to 3% to 8% of the total fibrinogen in the preoperative samples from these patients. Like the degradation products, these derivatives normally comprise less than 0.2% of the total fibrinogen Go Go Go 18,24,25 and were presumably elevated in the preoperative samples because of the vascular disease. However, unlike the degradation products, the concentrations of these high-molecular-weight, macromolecular derivatives fell during CPB. They disappeared almost entirely from the circulation of subjects who were made hypothermic and then returned to the circulation on restoration of normothermia in stages 4 and 5 (Figs. 5 and 6). There was little preferential disappearance of these derivatives in patients who were not made hypothermic (Fig. 5). The apparent temperature-mediated disappearance and return of these derivatives conformed with the known solubility behavior of fibrin complexes in the presence of heparin and calcium, caused by formation of cryoprecipitable calcium/heparin/fibrin(ogen)/fibronectin complexes. Go Go 26,27 Although refrigerator temperatures are usually required for precipitation of fibrinogen in such complexes, temperatures on the order of 28° C suffice for precipitation of fibrin monomer complexes with heparin. This was confirmed by tests made on stage 2 plasma samples in which the presence of EDTA prevented fibrin monomer and cross-linked fibrinogen dimers from being precipitated by the heparin in the samples, but these derivatives underwent full precipitation on recalcification of the plasmas at room temperature. They underwent only slight precipitation on recalcification of the plasmas at 37° C.

A question arose as to whether the fall in levels of factor XIIIA might have been due to a coprecipitation with the macromolecular fibrinogen derivatives, but little coprecipitation was observed in laboratory studies. When fibrin monomer was added to normal heparinized plasma the fibrin remained soluble at concentrations up to 10% of the total fibrinogen while it was held at 37° C, but formed precipitates at levels higher than 0.5% of the fibrinogen when chilled to 25° C. This precipitation of added fibrin monomer, which was verified electrophoretically by the GPR technique, Go 19 was not accompanied by more than a 10% reduction in plasma concentrations of factor XIIIA, as determined by immunoassay.

DISCUSSION

The findings of this study that we believe to be important were that (1) significant inverse correlations exist between levels of factor XIIIA and postoperative blood loss, (2) losses of factor XIIIA occur during initiation of CPB and result in further reductions in concentrations beyond the effects of hemodilution, and (3) heparin combined with hypothermia mediates a partially reversible precipitation of the elevated concentrations of macromolecular fibrinogen derivatives that occur in blood of patients with coronary artery disease. The correlations between levels of factor XIIIA and amounts of chest-tube drainage were significant only for periods 1 through 3, but we believe that an extended study would demonstrate significance for the finishing stages (4 and 5) as well. The correlations established thus far, though hovering near the p = 0.05 level for rejection of the statistical null hypothesis, can be considered impressive in view of the large number of variables apart from levels of factor XIIIA, particularly fibrinolysis, platelet activation and consumption, and leukocyte activation, which contribute to hemostasis during and after CPB. Go Go Go 7,28-31

Factor XIII is frequently overlooked as a factor for wound healing and control of bleeding, except in cases of inherited deficiencies in which its activity is lacking. That is because supplementation through transfusion of plasma or cryoprecipitate in congenital deficiencies provides a long-lasting benefit for month-long periods until plasma levels fall to within a small percentage of normal. However, needs for wound healing after major operations are not analogous to normal needs. Indeed, recent studies on subjects with heterozygotic congenital deficiencies who had levels of factor XIIIA on the order of 50% of normal indicated that these subjects are prone to bleed excessively after both simple and extensive surgical procedures. Go Go 32,33 A large multicenter trial in Japan to assess the effects of supplementation of plasma factor XIII in 71 patients with impaired wound healing indicated that there was significant benefit as determined by an independent committee on review of photographs, radiographs of fistulas, drainage volumes, and wound areas of treated versus untreated subjects. Go 34

The reason for the fall in factor XIIIA concentrations beyond dilutional decline during initiation of CPB is not known. A possibility that it was coprecipitating with the macromolecular fibrin (ogen) derivatives could not be supported from laboratory studies, but those studies were based on measurements under conditions in which there was negligible proteolytic activation of the XIIIA. Factor XIIIA becomes activated by thrombin in the course of blood coagulation. Go 35 Because of heparinization, little activation by thrombin would be expected. However, other potential activators released or potentiated by surface phenomena may contribute to the fall. Activated XIIIA could undergo greater coprecipitation with the macromolecular fibrin(ogen) derivatives than that observed with nonactivated XIIIA, because of strengthening of binding to fibrin subsequent to activation. Go 36

The disappearance of fibrin complexes and fibrinogen dimers from plasma during CPB in patients undergoing hypothermia and the partial reappearance of these derivatives on restoration of normothermia were attributed to incorporation of the derivatives into complexes with heparin, fibronectin, and calcium. We did not measure fibronectin levels in the plasma during CPB, but others have shown that it undergoes large heparin-induced reductions in association with hypothermia. Go 37 The studies on fibronectin were done with heparin dosages ten times greater than those used in the present study, but laboratory studies by Stathakis and associates Go 26 showed that fibronectin is an essential component in the heparin-induced precipitation. We suspect that the precipitation occurred within the patients' circulation and was not restricted to the oxygenator, because much of the return of the derivatives occurred after the bypass was discontinued. Recent studies have shown that patients who undergo normothermic systemic perfusion tend to bleed less. Go 13 Except for the pronounced disappearance of macromolecular fibrin (ogen) under hypothermic conditions, we did not uncover other differences between normothermic perfusion in this study, but suspect that differences would be found in an expanded study, which we believe would be justified in light of the present findings.

The need for homologous blood transfusion associated with CABG has fallen dramatically from the 20 to 30 units required in the early 1950s to about 10 units in the 1960s and early 1970s to only an occasional unit in the early 1980s largely because of improved extracorporeal pumps and oxygenators Go 38 and improved blood conservation techniques implemented at our institution. However, several factors have evolved in the past decade that have led to a continuing increase in perioperative bleeding in association with cardiac operations. These were accompanied by an increase in frequency of surgical exploration for hemostasis.

Factors independent of bleeding, including advanced age, reduced red cell mass, small body surface area, female gender, and preexisting anemia, have been shown to be associated with an increased need for homologous blood transfusions. Go 39 Also, complex surgical procedures, reoperations, emergency operations, and preoperative therapy with aspirin or fibrinolytic drugs are associated with increased bleeding. Go Go 40-42 They exacerbate the coagulation and platelet abnormalities that accompany the performance of CPB, including activation of complement, fibrinolysis, inadequate reversal of heparin, and heparin rebound. Because more patients undergoing CABG have increased risk factors for bleeding and need homologous blood transfusions, there has been an increased awareness of the potential complications associated with transfused blood, in particular transmission of hepatitis and human immunodeficiency virus infection. Currently used methods to decrease the need for homologous blood supplementation include meticulous hemostasis and intraoperative blood salvage, as well as preoperative autodonation of red blood cells and platelet-rich plasmapheresis. Therapy with deamino-8-D-arginine vasopressin, {epsilon}-aminocaproic acid, and aprotinin has been used extensively to improve platelet function and inhibit fibrinolysis and serine proteases.

In view of the present findings, low levels of factor XIIIA should be included among the list of risk factors for postoperative blood loss. None of the patients we studied had excessive bleeding, and none received whole blood, plasma, or platelets. We anticipate from case studies already cited that low levels of factor XIIIA will have an additive effect on other causes of bleeding associated with cardiac operations. We found that in 6 of 19 patients XIIIA levels decreased to 30% of normal during CPB. Soft clots and oozing of wounds remain major concerns in postoperative care. It would be of benefit if those concerns could be minimized. When the need for blood supplementation arises, the preventive measures that might have been taken are too late.

The principal goal of the present study was to determine whether levels of postoperative bleeding might be related to levels of factor XIIIA. We view the observed correlations as warranting expanded study. A critical test of the importance of factor XIIIA would be to assess whether supplementation can be of benefit in patients with low levels. The availability of recombinant factor XIIIA now makes it feasible to examine that question Go 21 and also warrants consideration that supplementation might offer therapeutic or prophylactic advantages for subjects who have low preoperative levels of factor XIIIA or who have excessive postoperative bleeding or poor wound healing. Laboratory studies with preactivated XIIIA indicate that high levels of factor XIII activity do not promote fibrin deposition, but serve to fix fibrin in the form in which it is found. Go Go 43,44 It can prevent coagulation of soluble fibrin complexes circulating in the blood by fixing the complexes in soluble form and functioning to stabilize the fibrin that undergoes self-aggregation into a clot. Go Go 45,46 In a sense factor XIIIA functions as a molecular surgeon, sewing the molecules together in the form in which they are assembled.

Acknowledgments

David A. Urbanic and Veronica Valenzuela assisted in these studies. Ms. Valenzuela was the recipient of a Summer Student Stipend from the American Heart Association Northeast Ohio Affiliate, Inc.

References

  1. Kaplan JA, Campbell F, Estafanous FG, et al. Future trends in the management of coagulation disorders: a Miles, Inc., Pharmaceutical Division symposium. [Proceedings]. Elkhart, Ind.: Miles, 1991.
  2. Harker LA, Malpass TW, Branson HE, Hessel EA, Slichter SJ. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 1980;56:824-34.[Free Full Text]
  3. Giuliani R, Szarcer E, Aquino EM, Palumbo G. Fibrin-dependent fibrinolytic activity during extracorporeal circulation. Thromb Res 1991;61:369-73.[Medline]
  4. Vander Salm TJ, Ansell JE, O'Kike ON, et al. The role of epsilon-aminocaproic acid in reducing bleeding after cardiac operation: a double-bland randomized study. J THORAC CARDIOVASC SURG 1988;96:538-40.
  5. Horrow J, Hlavacek J, Strong MD, et al. Prophylactic tranexaminic acid decreases bleeding after cardiac operations. J THORAC CARDIOVASC SURG 1990;99:70-4.[Abstract]
  6. Spiess BD, Logas DA, Tuman KJ. Thromboelastography used for detection of perioperative fibrinolysis: a report of four cases. J Cardiothorac Anesth 1988;2:666-72.[Medline]
  7. Bidstrup BP, Royston D, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high-dose aprotinin (Trasylol). J THORAC CARDIOVASC SURG 1990;97:364-72.[Abstract]
  8. Royston D. The serine antiprotease aprotinin (Trasylol): a novel approach to reducing postoperative bleeding. Blood Coagul Fibrinolysis 1990;1:55-69.[Medline]
  9. Dietrich W, Barankay A, Hähnel C, Richter JA. High dose aprotinin in cardiac surgery: three years' experience in 1,784 patients. J Cardiothorac Vasc Anesth 1992;6:324-7.[Medline]
  10. Vedrinne C, Girard C, Jegaden O, et al. Reduction in blood loss and blood use after cardiopulmonary bypass with high-dose aprotinin versus autologous fresh whole blood transfusion. J Cardiothorac Vasc Anesth 1992;6:319-23.[Medline]
  11. Alajamo F, Calamai G, Perna AM, et al. High-dose aprotinin: hemostatic effects in open heart operations. Ann Thorac Surg 1989;48:536-9.[Abstract]
  12. Khuri SF, Wolfe JA, Josa M, et al. Hematologic changes during and after cardiopulmonary bypass and their relationship to the bleeding time and nonsurgical blood loss. J THORAC CARDIOVASC SURG 1992;104:94-107.[Abstract]
  13. Yau TM, Carson C, Weisel RD, et al. The effect of warm heart surgery on postoperative bleeding. J THORAC CARDIOVASC SURG 1992;103:1155-63.[Abstract]
  14. Thurer RL, Loop FD, Lytle BW, Cosgrove DM. The conservation of blood during cardiac surgery. Clin Cardiol 1979;2:155-7.[Medline]
  15. Atencio AC, Reeve EB. Studies on the metabolism and distribution of fibrinogen in young and older rabbits: II—results. J Lab Clin Med 1965;66:20-33.
  16. McFarlane AS. In vivo behavior of I 131-fibrinogen. J Clin Invest 1963;42:346-61.
  17. Greenberg CS, Shuman MA. The zymogen forms of blood coagulation factor XIII bind specifically to fibrinogen. J Biol Chem 1982;257:6096-101.[Abstract/Free Full Text]
  18. Shainoff JR, Urbanic DA, DiBello PM. Immunoelectrophoretic characterizations of the cross-linking of fibrinogen and fibrin by plasma- and tissue-transglutaminase: identification of a rapid mode of hybrid {alpha}/{gamma}-chain cross-linking that is promoted by the {alpha}/{gamma}-chain cross-linking. J Biol Chem 1991;266:6429-37.[Abstract/Free Full Text]
  19. Shainoff JR, Urbanic DA, DiBello PM, Valenzuela V. GPR-phoresis: a novel approach to determining fibrin monomer and other macromolecular derivatives of fibrinogen and fibrin in blood. Blood Coagul Fibrinolysis 1993;4:87-92.[Medline]
  20. Clauss A. Gerrinungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957;17:237-46.[Medline]
  21. Bishop PD, Teller DC, Smith RA, Lasser GW, Gilbert T, Seale RL. Expression, purification and characterization of human factor XIII in Saccharomyces cerevisiae. Biochemistry 1990;28:1861-9.
  22. Weeke B. Rocket immunoelectrophoresis. Scand J Immunol 1973;2(Suppl):37-46.[Medline]
  23. Shainoff JR, Valenzuela R, Graor R, Urbanic DA, DiBello PM. Electrophoretic characterizations of cross-linked fibrinogen derivatives in blood and vascular tissue by zonal immobilization on glyoxyl agarose. Adv Exp Med Biol 1990;281:73-81.[Medline]
  24. Shainoff JR, Valenzuela R, Urbanic DA, DiBello PM, Lucas FV. Fibrinogen A{alpha} and {gamma}-chain dimers as potential differential indicators of atherosclerotic and thrombotic vascular disease. Blood Coagul Fibrinolysis 1990;1:499-503.[Medline]
  25. Valenzuela R, Shainoff JR, DiBello PM, et al. Immunoelectrophoretic and immunohistochemical characterizations of fibrinogen derivatives in atherosclerotic aortic intimas and vascular prosthesis pseudo-intimas. Am J Pathol 1992;141:861-80.[Abstract]
  26. Stathakis NE, Mosesson MW, Chen AB, Galanakis DK. Cryoprecipitation of fibrin-fibrinogen complexes induced by the cold-insoluble globulin of plasma. Blood 1978;51:1211-22.[Free Full Text]
  27. Stathakis NE, Mosesson MW. Interaction among heparin, cold-insoluble globulin, and fibrinogen in formation of the heparin-precipitable fraction of plasma. J Clin Invest 1977;60:855-65.
  28. Rinder CS, Bohnert J, Rinder HM, Mitchell J, Ault K, Hillman R. Platelet activation and aggregation during cardiopulmonary bypass. Anesthesiology 1991;75:388-93.[Medline]
  29. Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass. Blood 1990;76:1680-97.[Abstract/Free Full Text]
  30. Lu H, Coria C, Commin PL, et al. Hemostasis in patients undergoing extracorporeal circulation: the effect of aprotinin (Trasylol). Thromb Haemost 1991;66:633-7.[Medline]
  31. Teufelsbauer H, Proidl S, Havel M, Vukovich T. Early activation of hemostasis during cardiopulmonary bypass: evidence of thrombin mediated hyperfibrinolysis. Thromb Haemost 1992;68:250-2.[Medline]
  32. Berliner SH, Lusky A, Zivelin A, Modan M, Seligsohn U. Hereditary factor XIII deficiency: report of four families and definition of the carrier state. Br J Haematol 1984;58:495-505.
  33. Egbring R, Seitz R, Gürten M, et al. Bleeding complications in heterozygotes with congenital factor XIII deficiency. In: Mosesson MW, Amrani DL, Siebenlist KR, Diorio JP, eds. Fibrinogen 3: biochemistry, biological functions, gene regulation and expression. Amsterdam: Elsevier Science, 1988:341-6.
  34. Mishima Y, Nagao F, Ishibiki K, Matsuda M, Nakamura N. Faktor XIII in der Behandlung postoperativer therapierefraktärer Wundheilungsstörungen: Ergebnisse einer kontrollierten Studie. Chirurgie 1984;55:803-8.
  35. Lorand L, Konishi K. Activation of fibrin stabilizing factor of plasma by thrombin. Arch Biochem Biophys 1964;105:58-67.[Medline]
  36. Procyk R, Bishop PD, Kudryk B. Fibrin-recombinant human factor XIII A-subunit association. Thromb Res 1993;71:127-38.[Medline]
  37. Charash WE, Foster ED, Saba TM, Claire D, Cho E. Plasma fibronectin levels during cardiopulmonary bypass. J Appl Physiol 1990;69:1644-50.[Abstract/Free Full Text]
  38. Estafanous FG. Bleeding hearts: the Cleveland Clinic experience. In: Future trends in the management of coagulation disorders: a Miles, Inc., Pharmaceutical Division symposium. [Proceedings]. Elkhart, Ind.: Miles, 1991:1-4.
  39. Cosgrove DM, Loop FD, Lytle BW, et al. Determinants of blood utilization during myocardial revascularization. Ann Thorac Surg 1985;40:380-4.[Abstract]
  40. Salomon NW, Bigelow JC, Metzdorff MT. Reoperative coronary surgery: comparative analysis of 6591 patients undergoing primary bypass and 508 patients undergoing reoperative coronary artery bypass. J THORAC CARDIOVASC SURG 1990;100:250-60.[Abstract]
  41. Becker RC, Alpert JS. The impact of medical therapy on hemorrhagic complications following coronary artery bypass grafting. Arch Intern Med 1990;150:2016-21.[Abstract/Free Full Text]
  42. Bashein G, Nessly ML, Rice AL, Counts RB, Misbach GA. Preoperative aspirin therapy and reoperation for bleeding after coronary artery bypass surgery. Arch Intern Med 1991;151:89-93.[Abstract/Free Full Text]
  43. Dardik BN, Shainoff JR. Cross-linking of monomeric fibrin by fibrin stabilizing factor. Thromb Haemost 1979;42:864-72.[Medline]
  44. Shainoff JR, Dardik BN. Effects of cross-linking on clearance of circulating {alpha}-fibrin monomer and its complexes. J Lab Clin Med 1990;115:314-23.[Medline]
  45. Sasaki T, Page IH, Shainoff JR. Stable complex of fibrinogen and fibrin. Science 1966;152:1069-71.[Abstract/Free Full Text]
  46. Kanaide H, Shainoff JR. Cross-linking of fibrinogen and fibrin by fibrin-stabilizing factor. J Lab Clin Med 1975;85:574-97.[Medline]



This article has been cited by other articles:


Home page
 Asian Cardiovasc. Thorac. Ann.Home page
S. S Samra, N. S Samra, A. Jain, and V. Mehta
Video-Assisted Thoracic Surgery for Hemothorax Following Coronary Artery Bypass
Asian Cardiovasc Thorac Ann, April 1, 2006; 14(2): e19 - e20.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
R. Ponce, K. Armstrong, K. Andrews, J. Hensler, K. Waggie, J. Heffernan, T. Reynolds, and M. Rogge
Safety of Recombinant Human Factor XIII in a Cynomolgus Monkey Model of Extracorporeal Blood Circulation
Toxicol Pathol, October 1, 2005; 33(6): 702 - 710.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
P. Wettstein, A. Haeberli, M. Stutz, M. Rohner, C. Corbetta, K. Gabi, T. Schnider, and W. Korte
Decreased Factor XIII Availability for Thrombin and Early Loss of Clot Firmness in Patients with Unexplained Intraoperative Bleeding
Anesth. Analg., November 1, 2004; 99(5): 1564 - 1569.
[Abstract] [Full Text] [PDF]

Home page
 PerfusionHome page
E. J Fransen, D. S de Jong, W. T. Hermens, and J. G Maessen
Is postoperative blood loss, loss of blood? A pilot study in cardiac surgical patients
Perfusion, July 1, 2001; 16(4): 301 - 308.
[Abstract] [PDF]

Home page
 Ann. Thorac. Surg.Home page
G. J. Despotis and L. T. Goodnough
Management approaches to platelet-related microvascular bleeding in cardiothoracic surgery
Ann. Thorac. Surg., August 1, 2000; 70(2): S20 - 32.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. Anwar, L. Gallivan, S. D. Edmonds, and A. F. Markham
Genotype/Phenotype Correlations for Coagulation Factor XIII: Specific Normal Polymorphisms Are Associated With High or Low Factor XIII Specific Activity
Blood, February 1, 1999; 93(3): 897 - 905.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
E. M. Boyle Jr, E. D. Verrier, and B. D. Spiess
Endothelial Cell Injury in Cardiovascular Surgery: The Procoagulant Response
Ann. Thorac. Surg., November 1, 1996; 62(5): 1549 - 1557.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
J. R. Shainoff, G. B. Smejkal, P. M. DiBello, O. V. Mitkevich, P. J. Levy, C. E. Dempfle, and H. Lill
Isolation and Characterization of the Fibrin Intermediate Arising from Cleavage of One Fibrinopeptide A from Fibrinogen
J. Biol. Chem., September 27, 1996; 271(39): 24129 - 24137.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Floyd D. Loop
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shainoff, J. R.
Right arrow Articles by Loop, F. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shainoff, J. R.
Right arrow Articles by Loop, F. D.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS